The use of a risk assessment tool is also stressed importantly in both guidelines. These include the use of statin based therapy in subjects with a) established atherosclerosis, b) most subjects with diabetes mellitus and c) those with a low density lipoprotein cholesterol (LDL-C) above 190 mg/dl (5 mmol/L) regardless of risk. Of the four primary recommendations for treatment in the ACC/AHA guidelines, three parallel the primary recommendations from the CCS group. What is concordant between the US and Canadian dyslipidemia guidelines? We will review the similarities, differences and implications of the new guidelines compared with the recently published Canadian standards. The writing group is to be congratulated for proposing substantive changes that aim to treat a larger proportion of the population at risk and simplify the process for the front-line treating clinician. These new guidelines have incorporated many new features that are substantially different than previous US, Canadian or European publications. 3 The guidelines needed to adhere to specific rules with respect to the highest level of evidence from clinical trials and meta-analyses. The ACC/AHA guidelines followed a rigorous multi-year process implemented by the NHLBI, culminating in the recent document. The recent publication of the 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol has sparked strong opinion in the medical literature, creating opportunity to reinforce the importance of this topic. Harmonization with guidelines by other societies as part of the Canadian Cardiovascular Harmonization of National Guidelines Endeavour (C-CHANGE) was adhered to. The new guidelines focused on the importance of risk assessment, the use of statins as primary pharmacological therapy and specific recommendations for lifestyle modification. 1 The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used under the auspices of the CCS. Recently, the 2012 Canadian Cardiovascular Society (CCS) Dyslipidemia guidelines were published. 
It is widely recognized that a more accessible approach is required for primary care clinicians to optimize risk reduction. Clinicians have relied on clinical practice guidelines from various stakeholder organizations to aid them in decision making. Despite this, there remains some knowledge translation gaps in the screening, diagnosis and treatment of dyslipidemia to prevent atherosclerotic disease.
Framingham risk score guidelines trial#
HMG Co-A reductase inhibitors (statins) are highly efficacious and the clinical trial evidence demonstrating benefit is unsurpassed. Dyslipidemia is an important and undertreated cardiovascular risk factor.
0 kommentar(er)
